TSX open
Loading markets…

Advertisement

PARTNER SPOTLIGHT

CIBC Investor's Edge

Get 200 free trades when you open an eligible CIBC Investor's Edge account.

  • 200 free stock & ETF trades
  • Unlimited commission-free trades on 180+ select ETFs
  • Offer ends September 30, 2026
Stocks/NASDAQ/ILMN

Illumina Inc (ILMN : NASDAQ)

Common Stock

$255.38

USD

+7.92 (3.20%)

Last updated: 2026-09-23

Follow ILMN

ILMN

Illumina Inc

Source:WealthAwesomeWealthAwesome
$62.47 (32.38%)
30 day period
$188.29$221.83$255.38Aug 12Sep 2Sep 23

Performance

1 Day

+3.20%

1 Week

+11.55%

1 Month

+14.41%

YTD

+60.53%

Key Statistics

Market Cap

$38.56B

52W High

$256.17

52W Low

$88.00

P/E Ratio

46.10

50 Day MA

$207.47

200 Day MA

$157.85

Beta

1.47

Dividend Yield

-

Advertisement

Technical Indicators

Price vs 50-Day SMA

Above 50 SMA

Price vs 200-Day SMA

Above 200 SMA

Recent Price History

DateOpenHighLowCloseAdj CloseVolume
9/23/2026$248.79$256.17$247.00$255.38$255.382,301,113
9/22/2026$237.09$248.16$234.57$247.46$247.462,620,958
9/21/2026$241.50$248.31$238.26$238.82$238.823,102,860
9/18/2026$249.13$250.06$236.42$239.62$239.6232,586,500
9/17/2026$233.85$246.76$232.99$245.18$245.183,670,248
9/16/2026$224.49$236.00$223.70$228.93$228.933,371,996
9/15/2026$208.95$226.76$207.90$222.29$222.293,148,966
9/14/2026$206.74$208.93$202.81$208.21$208.212,060,457
9/11/2026$201.81$208.39$200.01$206.45$206.452,412,436
9/10/2026$203.69$206.07$200.56$201.27$201.271,294,600

Analyst Price Targets

Based on 20 analysts covering ILMN · as of Sep 17, 2026

📉

Wall Street analysts forecast ILMN stock price to fall 20.6% over the next 12 months.

Consensus

Buy

3.75 / 5.00

Avg. Target

US$202.65

-20.6% Upside

Current Price

US$255.38

Last close

Analyst Breakdown (20 analysts)

Strong Buy 8
Buy 3
Hold 6
Sell 2
Strong Sell 1
Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on ILMN's historical volatility

HistoricalForecast68%95%
US$154.32US$239.97US$325.61US$411.26US$496.91US$582.56TodayJun 17Aug 6Sep 23Nov 5Dec 19Jan 31

30-Day Vol

51.6%

Annualized

90-Day Vol

45.3%

Annualized

Trend (90d)

+50.0%

Annualized drift

90d Mean

US$305.31

Expected price

HorizonExpected68% Range (1σ)
30 trading daysUS$271.04US$226.85US$323.84
60 trading daysUS$287.67US$223.65US$370.00
90 trading daysUS$305.31US$224.31US$415.55

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

About Illumina Inc

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Financials

Revenue (TTM)
$4.49B
EBITDA
$1.16B
Profit Margin
18.34%
ROE (TTM)
32.34%
EPS (Diluted)
5.54
Book Value
18.80

Classification

Sector
Health Care
Industry
Life Sciences Tools & Services
Group
Pharmaceuticals, Biotechnology & Life Sciences

7 stocks to buy and hold forever

Blue-chip dividend stocks for long-term wealth building.

Get the FREE Report

Advertisement

Common Questions About ILMN.US

Market movers

Recent NASDAQ movers

Top 1-day gainers — updated from our Canadian movers feed.

All movers →
TickerNamePrice1D
BENFBeneficient Class A Common Stock$2.90+438.73%
JAGXJaguar Animal Health Inc$8.91+233.71%
WHLRWheeler Real Estate Investment Trust, Inc.$5.44+190.91%
VSATCTM Kids IT Education Inc.$3.64+83.84%
ARTLArtelo Biosciences Inc$7.31+76.14%
BFRGBullfrog AI Holdings, Inc. Common Stock$0.95+58.33%
VTGNVistaGen Therapeutics Inc$0.37+46.54%
IPDNProfessional Diversity Network Inc$5.42+38.97%

ILMN.US news timeline

1 article covering ILMN.US, most recent first

Latest

Why Illumina Inc stock went up yesterday

Stocks

Advertisement